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Diagnosis of Recurrent Uterine 
Cervical Cancer: Computed Tomography
versus Positron Emission Tomography
Objective: To determine the accuracy of CT and positron emission tomogra-
phy (PET) in the diagnosis of recurrent uterine cervical cancer.
Materials and Methods: Imaging findings of CT and PET in 36 patients (mean
age, 53 years) in whom recurrent uterine cervical cancer was suspected were
analyzed retrospectively. Between October 1997 and May 1998, they had under-
gone surgery and/or radiation therapy. Tumor recurrence was confirmed by
pathologic examination or follow-up studies.
Results: In detecting recurrent uterine cervical cancer, the sensitivity, specifici-
ty, and accuracy of CT were 77.8%, 83.3%, and 80.5%, respectively, while for
PET, the corresponding figures were 100%, 94.4%, and 97.2%. The Chi-square
test revealed no significant difference in specificity (p = .2888), but significant dif-
ferences in sensitivity (p = .0339) and accuracy (p = .0244).
Conclusion: PET proved to be a reliable screening method for detecting recur-
rent uterine cervical cancer, but to determine the anatomical localization of recur-
rent tumors, and thus decide an adequate treatment plan, CT was eventually
needed.
he recurrence rate of uterine cervical cancer is reported to be 6.5% after
surgery and 26.2% after radiation therapy alone (1). Radiological studies
such as intravenous urography (IVU), US, CT, and MR imaging are used
to detect recurrent cervical cancer (2). It is difficult, however, for these imaging modali-
ties to differentiate recurrent tumor from postoperative or radiation fibrosis, and to de-
tect metastatic normal-sized lymph nodes and extrapelvic metastases (2 7).
Since Di Chiro et al. (8) first used it to detect recurrent brain tumors, positron emis-
sion tomography (PET), the diagnostic modality which makes use of increased glycoly-
sis in tumor cells, has been used to detect recurrent tumors in many organs.
To our knowledge, no report has described the diagnosis of recurrent cervical cancer
using PET. The purpose of this study is to compare the accuracy of CT with that of
PET in the detection of recurrent cervical cancer.
MATERIALS AND METHODS
Among patients with uterine cervical cancer who had undergone initial treatment
between October 1997 and May 1998, CT and PET were performed in 36 in whom
recurrence was clinically suspected. As initial treatment, 13 patients had undergone
surgery alone, 14 radiation therapy alone, and nine surgery and postoperative radia-
tion therapy. Recurrence was suspected on the basis of increased levels of serum squa-
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Tmous cell carcinoma antigen (SCCA) and carcinoembryon-
ic antigen (CEA), pain in the lower abdomen and back,
edema of the lower leg, and oliguria.
All patients underwent CT and PET, the former involv-
ing the use of a GE CT/i 9800 scanner (General Electric
Medical Systems, Milwaukee, WI), with 10mm thickness.
Images of the chest, abdomen, and pelvis were obtained af-
ter intravenous injection of 150 ml non-ionic contrast me-
dia. For PET, 18F-FDG (2-[fluorine-18]fluoro-2-deoxy-D-
glucose) with a GE Advance scanner (General Electric
Medical Systems, Milwaukee, WI) was used. During the six
hours prior to scanning, patients were restricted to orally
and intravenously administered glucose. In the PET room,
10mCi of FDG was administered intravenously prior to in-
travenous hydration with one liter of normal saline. Thirty
minutes after the administration of FDG, Lasix 20 mg was
intravenously injected. To avoid artifactual accumulation
of FDG in the urinary bladder, a Foley catheter with drai-
nage bag was then positioned.
Two radiologists (DHP, KHK) and one nuclear medicine
physician (CWC) retrospectively analyzed the imaging find-
ings. As seen on CT, definite metastatic mass or a nodule
and lymph node larger than 1 cm along the short axis were
interpreted as positive findings. On PET, we interpreted a
high metabolic area of over 2.5 ml/kg of SUV (standardized
uptake value; mean activity of region of interest [mCi/
ml]/injected dose [mCi/ ml]/body weight[kg]) as a positive
finding. Recurrence was confirmed by percutaneous lymph
node biopsy in ten patients, biopsy of the pelvic mass in
three and by follow-up study in 23. Tumor marker study
and CT at 3- and 6-month intervals were used for follow
up, which in most patients lasted for 18 to 24 months.
Where either 1) increased tumor marker, 2) increased size
of masses or lymph nodes, as seen on CT, or 3) decreased
size of masses and lymph nodes after radiation therapy and
chemotherapy was noted, it was considered that the condi-
tion had recurred.
In addition, the location and extension of recurrent mass-
es or metastatic lymph nodes were analyzed for surgical
extirpation and determination of radiation portal.
RESULTS
In 18 patients, recurrence was confirmed by pathologic
examination and follow-up study. CT revealed three false-
positive cases and four false negatives, while on PET there
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Fig. 1. A 39-year-old woman who had undergone radical hysterectomy due to uterine cervical carcinoma.
A. Enhanced CT scan shows soft tissue mass on the left pelvic side wall (arrow).
B. PET scan shows no hypermetabolic site in the pelvis. Since no interval change was seen during follow-up study, we concluded that this
was a case of postoperative fibrosis. The highly metabolic lesion in left abdomen (arrow) is due to artifactual accumulation of FDG in as-
cending colon.
Table 1. Results of CT and PET for the Detection of Recur-
rent Uterine Cervical Cancer
TP FP FN TN Sens. Spec. Accu.
(%) (%) (%)
CT 14 3 4 15 77.8 83.3 80.5
PET 18 1 0 17 100 94.4 97.2
Note. TP = true positive, FP = false positive, FN = false negative,
TN = true negative, Sens = sensitivity, Spec. = specificity, 
Accu. = accuracywas only one false positive. On CT, sensitivity, specificity,
and accuracy were 77.8%, 83.3%, and 80.5%, respective-
ly, while for PET, the corresponding figures were 100%,
94.4%, and 97.2% (Table 1).
The three false-positive cases interpreted as recurrence
of soft tissue masses in the pelvic cavity and seen on CT
showed no high metabolic area on PET, and were shown
by follow-up study to be postoperative or radiation fibrosis
(Fig. 1). The four false-negative cases seen on CT and inter-
preted as  no recurrence were lymph nodes smaller than
1 cm in the abdomen, pelvic cavity, and inguinal area (Fig.
2). Unfortunately, however, they showed a high metabolic
area and were confirmed by follow-up percutaneous biop-
sy or increased size as recurrence. The one false-positive
case thought because of the high metabolic area seen on
PET in the left upper lung field to be recurrence, was
shown by follow-up study and sputum polymerase chain
reaction to be tuberculosis (Fig. 3).
Due to poor spatial resolution, PET failed to detect the
extent of recurrent pelvic masses and the exact level of
lymph nodes. To determine the possibilities of surgery and
the required extent of radiation therapy, CT was therefore
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Fig. 3. A 41-year-old woman with uterine cervical cancer. False positive PET scan due to pulmonary tuberculosis.
A. CT scan shows multiple nodules in left upper lung (arrows).
B. PET scan shows hypermetabolic lesion (SUV = 9.6ml/kg) in left upper lung (arrow). Tuberculosis was confirmed by polymerase chain
reaction of the sputum.
B A
Fig. 2. A 52-year-old woman who had undergone radiation therapy due to uterine cervical cancer.
A. Enhanced CT scan shows lymph node smaller than 1cm in the para-aortic area (arrow).
B. PET scan shows hypermetabolic area (SUV = 3.8ml/kg) in the para-aortic chain (arrow). 
ABneeded.
DISCUSSION
About half of all cases of recurrent uterine cervical can-
cer are confined to the pelvic cavity, but some cases show
metastatic lesions in the lymph nodes, lung, bone, and liver
(9). Halpin et al. (1) reported that where there is recur-
rence, 60 per cent of cases are diagnosed within two years,
and 82 per cent within four years. Eighty percent of pa-
tients in whom there was recurrence died within one year,
and ninety percent within two years.
The treatment of recurrent uterine cervical cancer differs
according to the extent of the recurrent lesion. If this is
confined to the pelvic cavity, pelvic exenteration is the
treatment of choice. On the other hand, if it recurs beyond
the pelvic cavity, radiation therapy or chemotherapy is
preferred. The detection and exact localization of a recur-
rent lesion are therefore very important (10).
Clinically, patients with recurrence complain of back
pain, sciatic pain, and edema of the lower leg, but some
show no symptoms or signs of recurrent cervical cancer (1,
2). Radiologic imaging studies such as IVU, barium enema,
lymphangiography, and US are used to detect recurrent u-
terine cervical cancer, but the findings are indirect (2).
In cases of recurrent cervical cancer, CT scanning demon-
strates a pelvic mass or enlarged pelvic and para-aortic
lymph nodes (2). The extent of a tumor, and lymphade-
nopathy and hydronephrosis, can be easily detected on CT
(2). CT scanning is also helpful in determining the radiation
portal, the site for biopsy, and the effect of treatment.
Consequently, the modality has been used as a gold stan-
dard in the diagnosis of recurrent uterine cervical cancer.
With CT scanning, however it may be difficult to differen-
tiate recurrence from postoperative and postradiation fi-
brosis, and to detect normal-sized metastatic lymph nodes
(2, 3). On MR images, a recurrent lesion shows increased
signal intensity on T2-weighted images, but reports of its
specificity and sensitivity have varied. In addition, MR can-
not distinguish necrosis, edema, hemorrhage and inflam-
mation from recurrence (4 7).
PET with FDG, which makes use of increased glycolysis
levels in tumor cells, is a noninvasive diagnostic method
used in functional imaging of the tumor, and has been used
to detect primary tumors and recurrence, to determine the
efficacy of therapy, for staging, and to detect the extent of
a tumor (11 25). Ogunbiyi et al. (20) compared PET with
CT in the detection of recurrent or metastatic colon and
rectal cancer. They reported that PET accurately detected
met-astatic lesions as well as local recurrences, and was es-
pecially effective in differentiating between recurrence and
postoperative fibrosis. Anzai et al. (12) compared PET
with CT and MR in recurrent head and neck cancer after
surgery or radiation therapy, and reported that local
hematoma, abscess, fistula, and reconstruction flap could
not be clearly differentiated from local recurrence. They al-
so reported that sensitivity and specificity were 88% and
100% with PET, but 25% and 75% with CT and MR, re-
spectively. Hudgins et al. (26) reported that in head and
neck cancer, MR could not easily distinguish between
postradiation fibrosis and recurrence. McGuirt et al. (18)
also reported that PET was superior to CT in terms of sen-
sitivity and specificity, and that if PET revealed no areas of
high metabolism, pathologic examination could be de-
layed.
PET is superior to CT in detecting small metastatic lymph
nodes, especially in patients in whom the fat content of the
retroperitoneum is low. Thus, PET is effective in distin-
guishing metastatic lymph nodes from testicular cancer,
lymphoma, and rectal and cervical cancer, which prefer to
metastasize to retroperitoneal lymph nodes. PET can also
differentiate recurrence from scar tissue, irrespective of
anatomical alteration and surgical clip (27). With CT, we
also experienced difficulty in differentiating recurrence
from postoperative and postradiation fibrosis and in de-
tecting small lymph nodes. PET can, in addition, be used to
obtain whole body images and detect recurrence that was
not clinically suspected. A disadvantage of PET is its high
cost; another is that it does not easily determine anatomical
location and tumor extent. Using PET, we were unable to
decide the exact location of a recurrent mass and the ex-
tent of invasion of an adjacent organ. Eventually, there-
fore, in order to decide the treatment plans of patients in
whom recurrence was detected, CT was required.
In conclusion, PET is a reliable diagnostic screening
modality. It can detect small lymph nodes, distinguish be-
tween recurrence and fibrosis, and can be used for whole-
body scanning. Tumor localization is not one of its stren-
gths, however, and in order to determine a treatment plan,
CT scanning is therefore necessary.
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